All In Biotech

BLA 761111 · Hospira INC

Nyvepria

Pegfilgrastim-Apgf · Injection · Leukocyte Growth Factor

Last checked: Nov 20, 2026Latest source record: May 21, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Jun 10, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

400

72 Phase 3, 30 recruiting

FAERS reports

198

118 serious, 22 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 2, 2026.

Patients with Cancer Receiving Myelosuppressive Chemotherapy NYVEPRIA is indicated in adults and pediatric patients aged newborn and older to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia [see Dosage and Administration (2.1) and Clinical Studies (14) ] . NYVEPRIA is a leukocyte growth factor indicated in adults and pediatric patients aged newborn and older to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. ( 1 ) Limitations of Use NYVEPRIA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. ( 1 ) Limitations of Use NYVEPRIA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Mechanism: Pegfilgrastim products are colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • NYVEPRIA · PEGFILGRASTIM-APGF 6MG/0.6ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pegfilgrastim" as an intervention, any sponsor and status, largest first.

All 400 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death23
  • off label use17
  • pyrexia15
  • drug dose omission by device12
  • device leakage11
  • nausea11
  • fatigue10
  • asthenia9
  • diarrhoea7
  • neutropenia7
  • device issue6
  • device operational issue6

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20213
202217
202335
202453
202567
202623

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nyvepria (PEGfilgrastim-Apgf)

2024 spending

$10.3M

Beneficiaries

767

2,486 claims

Per beneficiary

$13,388

$6,130.28 per unit

View as table
YearSpending
2020$0
2021$255,122
2022$1,211,038
2023$4,121,441
2024$10,268,216

Part B: Nyvepria (Pegfilgrastim-Apgf) · HCPCS Q5122

2024 spending

$9.5M

Beneficiaries

3,535

10,928 claims

Per beneficiary

$2,691

2024 ASP limit $76.01 per unit

View as table
YearSpending
2020$0
2021$26,671,091
2022$52,314,801
2023$33,412,196
2024$9,511,522

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 308 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.